Background: Plasmodium vivax malaria remains a major public health burden in Myanmar. Resistance to chloroquine (CQ), the first-line treatment for P. vivax, has been reported in the country and has potential to undermine local control efforts.
Methods: Patients over 6 years of age with uncomplicated P. vivax mono-infection were enrolled into clinical efficacy studies in Myawaddy in 2014 and Kawthoung in 2012. Study participants received a standard dose of CQ (25 mg/kg over 3 days) followed by weekly review until day 28. Pvmdr1 copy number (CN) and microsatellite diversity were assessed on samples from the patients enrolled in the clinical study and additional cross-sectional surveys undertaken in Myawaddy and Shwegyin in 2012.
Results: A total of 85 patients were enrolled in the CQ clinical studies, 25 in Myawaddy and 60 in Kawthoung. One patient in Myawaddy (1.2%) had an early treatment failure and two patients (2.3%) in Kawthoung presented with late treatment failures on day 28. The day 28 efficacy was 92.0% (95% CI 71.6-97.9) in Myawaddy and 98.3% (95% CI 88.7-99.8) in Kawthoung. By day 2, 92.2% (23/25) in Myawaddy and 85.0% (51/60) in Kawthoung were aparasitaemic. Genotyping and pvmdr1 CN assessment was undertaken on 43, 52 and 46 clinical isolates from Myawaddy, Kawthoung and Shwegyin respectively. Pvmdr1 amplification was observed in 3.2% (1/31) of isolates in Myawaddy, 0% (0/49) in Kawthoung and 2.5% (1/40) in Shwegyin. Diversity was high in all sites (H 0.855-0.876), with low inter-population differentiation (F 0.016-0.026, P < 0.05).
Conclusions: Treatment failures after chloroquine were observed following chloroquine monotherapy, with pvmdr1 amplification present in both Myawaddy and Shwegyin. The results emphasize the importance of ongoing P. vivax drug resistance surveillance in Myanmar, particularly given the potential connectivity between parasite population at different sites.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504659 | PMC |
| http://dx.doi.org/10.1186/s12936-017-1912-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Body Mass Index and Clinical Outcomes in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Acta Cardiol Sin
January 2025
School of Medicine, National Yang Ming Chiao Tung University.
Article Synopsis
- The study investigates the "obesity paradox," focusing on overweight and obese patients who underwent percutaneous coronary intervention (PCI) for coronary artery disease.
- Over a follow-up period averaging about 65 months, results showed that 17.4% of patients experienced adverse cardiovascular events, with a notable J-shaped relationship indicating that those classified as overweight (BMI 25.0-29.9 kg/m) had lower risks of total and major cardiovascular events.
- The findings suggest that overweight individuals may have better cardiovascular outcomes post-PCI compared to those with a normal BMI.
Rhythm Control Better Prevents Stroke than Rate Control in Patients with Concomitant Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Nationwide Population Based Cohort Study with Long-Term Follow-Up.
Acta Cardiol Sin
January 2025
Cardiovascular Center, Taichung Veterans General Hospital, Taichung.
Background: Atrial fibrillation (AF) increases the risks of stroke and mortality. It remains unclear whether rhythm control reduces the risk of stroke in patients with AF concomitant with hypertrophic cardiomyopathy (HCM).
Methods: We identified AF patients with HCM who were ≥ 18 years old in the Taiwan National Health Insurance Database.
Objective: To investigate machine learning-based regression models to predict the postoperative apnea-hypopnea index (AHI) for evaluating the outcome of velopharyngeal surgery in adult obstructive sleep apnea (OSA) subjects.
Study Design: A single-center, retrospective, cohort study.
Setting: Sleep medical center.
Efficacy of Hongjing I granule, an herbal medicine, in patients with mild to moderate erectile dysfunction in a randomized controlled trial.
Front Pharmacol
December 2024
Department of Urology, School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Background: HJIG is a potential treatment for erectile dysfunction (ED) that has been used in China for over 20 years. We conducted a multi-center, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of the Chinese Herbal Medicine, Hongjing I granule (HJIG), in patients with mild to moderate erectile dysfunction (ED).
Methods: This study is structured as a randomized, double-blind, placebo-controlled trial, executed across multiple centers.
Randomized Controlled Trials for Platelet-Rich Plasma Use in Knee Osteoarthritis Rarely Report Key Sociodemographic Patient Variables: A Scoping Review.
Arthrosc Sports Med Rehabil
December 2024
Department of Orthopaedic Surgery, The Keck School of Medicine, University of Southern California, Los Angeles, California, U.S.A.
Purpose: To investigate the characteristics and rate of sociodemographic variables reported in randomized controlled trials (RCTs) studying platelet-rich plasma (PRP) injections in the treatment of knee osteoarthritis (OA).
Methods: In January 2024, PubMed, Scopus, and Web of Science databases were queried for the phrase "Platelet-Rich Plasma Knee Osteoarthritis." Included studies were RCTs investigating PRP use in knee OA published in English between 2012 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!